Latest Manufacturing News

Castile Resources has kicked off pilot plant bench scale testing for its Rover 1 project, integrating a 41% resource upgrade and higher metal prices into its Bankable Feasibility Study. The company also secured $8.4 million in funding and is preparing for exploration drilling amid regional consolidation.

FINEOS Corporation Holdings PLC reported its strongest quarterly cash inflow ever alongside key contract wins in Australia and North America, maintaining its FY26 revenue guidance and advancing AI integration in its insurance software platform.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

IperionX has transitioned its Virginia titanium operations to continuous 24/7 production, ramping proprietary HAMR™ titanium powder output to 4.2 metric tons in March and targeting 200 tons per annum by the end of 2026. Alongside manufacturing capacity expansions and strong U.S. Department of War backing, the company advances its critical minerals project in Tennessee.

Gale Pacific reported a $1.3 million operating cash outflow in Q3 FY26 amid Middle East geopolitical tensions but strengthened its net cash position by $18 million year-on-year. The company is executing a revised strategy focused on expanding its US commercial footprint and diversifying manufacturing beyond China.

Alterity Therapeutics has secured FDA alignment on the chemistry and manufacturing controls for its ATH434 Phase 3 trial in Multiple System Atrophy, marking a pivotal regulatory milestone ahead of the planned mid-2026 End-of-Phase 2 meeting.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Adisyn has confirmed a major graphene breakthrough compatible with semiconductor manufacturing and secured exclusive radar absorption rights, backed by a $14 million placement led by top institutional investors.

Fortuna Metals (ASX: FUN) has extended the rutile mineralisation footprint at its Mkanda Project in Malawi from 37km² to 53km², revealing high-grade cores and planning extensive drilling to underpin a maiden resource estimate in the second half of 2026.

Sarytogan Graphite Limited has upgraded its Central Graphite Zone resource, marking a key milestone with Measured classification and progressing its Definitive Feasibility Study. Meanwhile, copper exploration reveals promising anomalies, backed by fresh capital injections.